TABLE III.
Gene ontology profile of esophageal epithelial cells exposed to IL-13 with or without E2
| Group | Ontology | Activity | No. of genes | P value | Specific genes |
|---|---|---|---|---|---|
| Vehicle vs vehicle plus IL-13 (n = 246) | Biological process | Regulation of cell adhesion | 17/709 | 9.38E-05 | CYP1B1, C1QTNF1, COL1A1, DPP4, SFRP1, TNFSF18, TNC, C13orf15, MAP3K14, ST6GAL1, APOD, TGM2, RASGRP1, THBS1, EGR3, CD59, B4GALNT2 |
| Biological process | Regulation of endothelial cell proliferation | 6/103 | 2.27E-04 | CCL26, CCL24, C13orf15, ARG1, THBS1, EGR3 | |
| Biological process | Response to cytokine | 18/825 | 1.89E-04 | CHI3L1, CCL26, IL22RA1, CISH, MME, CCL24, PID1, CARD14, COL1A1, SFRP1, TNFSF18, MAP3K14, BIRC3, IFI35, ARG1, ENTPD2, OASL, SOCS1 | |
| Vehicle vs E2 (n = 125) | Biological process | Cellular oxidant detoxification | 4/87 | 1.61E-04 | SZT2, HBA1, HBA2, HBB |
| Biological process | Gene silencing | 6/257 | 1.52E-04 | KMT2B, POLR2A, TERT, KMT2D, HIST1H4H, MSL3P1 | |
| Vehicle + IL-13 vs E2 + IL-13 (n = 100) | Biological process | Response to oxidative stress | 4/440 | 4.32E-04 | KLF2, HBA1, HBA2, HBB |
| Cellular component | Innate immune response in mucosa | 2/24 | 1.86E-04 | HIST1H2BJ, HIST1H2BC | |
| Vehicle vs E2 plus IL-13 (n = 1107) | Biological process | Mitotic cell cycle process | 96/932 | 3.39E-11 | NUSAP1, KIF18A, MIS18BP1, SPC25, MCM6, CDC7, CDC45, FZR1, ANAPC10, NDC80, ANXA1, RGCC, BIRC3, STIL, SMC2, NUP35, NDC1, HAUS1, MARK4, REEP4, PLK4, TJP3, PBK, NEDD1, BID, NCAPG, DBF4, BUB1, BUB1B, NPM1, CALM2, NUMA1, TERT, ZWINT, CCNB1, ITGB3BP, ORC4, ORC5, CCNE2, BRD4, MASTL, CDK1, CDC6, CDC34, TOP2A, PCNA, CDK7, CDKN3, PTTG1, CENPC, CENPE, ORC3, CETN2, CETN3, CHEK1, HMMR, TTK, CKS2, ANLN, PIM1, NUP37, ASPM, DSCC1, HSPA2, PLK3, HSP90AA1, TOM1L2, VRK1, KIF23, POLE2, NABP1, EPGN, KIF20B, PRIM1, TNKS1BP1, TCF7L1, KNTC1, ERCC6L, PSMA2, PSMA3, PSMA4, DLGAP5, PSMC6, NUF2, SPDL1, KNL1, ZWILCH, NUP107, RBBP8, RPS27L, CEP55, FANCI, CKAP2, SKA3, RPA3, MAD2L1 |
| Biological process | Keratinocyte differentiation | 19/140 | 9.55E-05 | EVPL, ALOX15B, FLG, FOXN1, ANXA1, TMEM79, ADAM9, CASP3, LCE1A, TGM1, C1orf68, CDSN, CASP14, OVOL2, PPL, CSTA, DNASE1L2, KRT10, LOR | |
| Biological process | Skin development | 33/280 | 7.14E-06 | EVPL, ALOX12B, ALOX15B, FLG, FOXN1, ANXA1, TMEM79, GRHL3, KRT27, ADAM9, SLC27A4, CASP3, LCE1A, TGM1, C1orf68, CDSN, CASP14, OVOL2, COL1A1, WNT7A, COL5A3, CLDN4, PPARD, PPL, IGFBP5, CSTA, TCF7L1, PRSS8, JUP, DNASE1L2, KRT10, LOR, ALOXE3 |
Column 1 is a comparison between the vehicle (0.01% EtOH) or E2 (100 nmol/L E2) treatment groups for 48 hours with or without addition of IL-13 (100 ng/mL) at 24 hours. Columns 2 and 3 represent gene ontology grouping and associated biological or cellular activity. Column 4 is the number of genes dysregulated per ontologic grouping. Column 5 is the P value of an ontologic grouping association using the hypergeometric probability mass function. Column 6 represents individual genes from the ontologic grouping.